Letrozole
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-LETROZOLE |
|---|---|
| Type | Drug |
| Aliases | FemaraЛетрозол |
| Status | pending_clinical_signoff |
| Diseases | DIS-BREAST |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Drug Facts
| Class | Aromatase inhibitor (non-steroidal, third-generation) |
|---|---|
| Mechanism | Reversible non-steroidal AI similar to anastrozole. Slightly higher relative potency in some PK studies but clinically interchangeable. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Interchangeable with anastrozole. Often paired with CDK4/6i in metastatic HR+/HER2- 1L (e.g., PALOMA-2 letrozole + palbociclib).
Used By
Regimens
REG-AI-PALBOCICLIB- AI + palbociclib (HR+/HER2- metastatic 1L)REG-AI-RIBOCICLIB- AI + ribociclib (HR+/HER2- metastatic 1L; OS-validated)REG-RIBOCICLIB-AI-ADJUVANT- Ribociclib adjuvant + AI (HR+/HER2- early breast cancer; NATALEE)